What is the Origin of Cardiovascular Risks of HRT?

This clinical concept gained prominence following the publication of major randomized controlled trials, notably the Women's Health Initiative (WHI), which systematically quantified the risks associated with specific oral estrogen and progestin combinations in postmenopausal women. The term represents a synthesis of epidemiological and clinical trial data, informing the current practice guidelines for hormone therapy. The debate around these risks continues to shape personalized prescribing strategies.

What is the Mechanism of Cardiovascular Risks of HRT?

Exogenous hormones can influence cardiovascular risk through several complex physiological pathways. Oral estrogen, for example, alters hepatic protein synthesis, leading to changes in coagulation factors and an increased propensity for thrombosis and venous thromboembolism. Furthermore, depending on the regimen, hormones can affect vascular endothelial function, lipid profiles, and inflammatory markers, collectively modulating the risk of atherosclerotic progression and acute cardiovascular events.

Cardiovascular Risks of HRT ∞ Area

Cardiovascular Risks of HRT

Meaning

Cardiovascular Risks of HRT refer to the potential for adverse events affecting the heart and vascular system associated with Hormone Replacement Therapy, including myocardial infarction, stroke, and venous thromboembolism. The clinical profile of these risks is highly dependent on the type, dose, route of administration, and timing of the hormonal intervention, as well as the patient’s pre-existing health status. Careful clinical assessment is mandatory to mitigate these serious complications.